{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:08:19Z","timestamp":1778846899575,"version":"3.51.4"},"reference-count":146,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012172","name":"Breast Cancer Canada","doi-asserted-by":"crossref","award":["#10"],"award-info":[{"award-number":["#10"]}],"id":[{"id":"10.13039\/100012172","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) has been associated with a poorer prognosis than other subtypes, due to its more aggressive behaviour. Since 2020, significant advances in locoregional and systemic therapy have improved outcomes for patients with TNBC, but the implementation of these treatments remains inconsistent across Canada. There is, therefore, a critical need for evidence-informed, consensus-driven guidance to support the integration of new therapies into practice. Research Excellence, Active Leadership Canadian Breast Cancer Alliance (REAL Alliance), a pan-Canadian group of breast cancer specialists and Breast Cancer Canada, a patient advocacy organization, convened to develop national clinical consensus recommendations for the management of breast cancer. Through a selective literature review and modified Delphi process of national experts in the fields of medical oncology, radiation oncology, surgical oncology and pharmacy, REAL Alliance developed national consensus recommendations for the management of TNBC. The result is a set of 23 recommendations: four overall general recommendations, 11 in early-stage TNBC, and eight in metastatic TNBC. These recommendations are intended for oncology healthcare professionals, and are intended to guide evidence-informed, consistent care across Canada.<\/jats:p>","DOI":"10.3390\/curroncol33050243","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T14:28:23Z","timestamp":1777040903000},"page":"243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6571-4587","authenticated-orcid":false,"given":"Christine","family":"Simmons","sequence":"first","affiliation":[{"name":"BC Cancer\u2014Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-5360","authenticated-orcid":false,"given":"Omar F.","family":"Khan","sequence":"additional","affiliation":[{"name":"Arthur J.E. Child Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-318X","authenticated-orcid":false,"given":"Christine","family":"Brezden-Masley","sequence":"additional","affiliation":[{"name":"Marvelle Koffler Breast Centre, Mount Sinai Hospital, University of Toronto, Toronto, ON M5G 1X5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1080-0998","authenticated-orcid":false,"given":"David W.","family":"Cescon","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University of Toronto, Toronto, ON M5G 2M9, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4201-8930","authenticated-orcid":false,"given":"Anil Abraham","family":"Joy","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2581-4903","authenticated-orcid":false,"given":"Nathalie","family":"LeVasseur","sequence":"additional","affiliation":[{"name":"BC Cancer\u2014Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna J.","family":"Jerzak","sequence":"additional","affiliation":[{"name":"Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4111-2757","authenticated-orcid":false,"given":"Karen A.","family":"Gelmon","sequence":"additional","affiliation":[{"name":"BC Cancer\u2014Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7434-2263","authenticated-orcid":false,"given":"Sandeep","family":"Sehdev","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital Cancer Centre, Ottawa, ON K1H 8L6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Chia","sequence":"additional","affiliation":[{"name":"BC Cancer\u2014Vancouver, University of British Columbia, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Webster","sequence":"additional","affiliation":[{"name":"Arthur J.E. Child Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Edwards","sequence":"additional","affiliation":[{"name":"Dr. H. Bliss Murphy Cancer Center, Memorial University of Newfoundland, St. John\u2019s, NL A1B 3V6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aalok","family":"Kumar","sequence":"additional","affiliation":[{"name":"BC Cancer\u2014Surrey, University of British Columbia, Vancouver, BC V5Z 4E6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey Q.","family":"Cao","sequence":"additional","affiliation":[{"name":"Arthur J.E. Child Cancer Centre, University of Calgary, Calgary, AB T2N 5G2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Boileau","sequence":"additional","affiliation":[{"name":"Jewish General Hospital, McGill University, Montreal, QC H3T 1E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kara","family":"Laing","sequence":"additional","affiliation":[{"name":"Dr. H. Bliss Murphy Cancer Center, Memorial University of Newfoundland, St. John\u2019s, NL A1B 3V6, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel","family":"Bouganim","sequence":"additional","affiliation":[{"name":"McGill University Health Centre, McGill University, Montr\u00e9al, QC H4A 3J1, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4344-7913","authenticated-orcid":false,"given":"Mita","family":"Manna","sequence":"additional","affiliation":[{"name":"Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, SK S7N 4H4, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of Patient Advocacy, Breast Cancer Canada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1503\/cmaj.240095","article-title":"Projected Estimates of Cancer in Canada in 2024","volume":"196","author":"Brenner","year":"2024","journal-title":"Can. Med. Assoc. J."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Wilkinson, A.N., Ng, C., Ellison, L.F., and Seely, J.M. (2025). Breast Cancer Incidence and Mortality, by Age, Stage and Molecular Subtypes, by Race\/Ethnicity in Canada. Oncologist, 30.","DOI":"10.1093\/oncolo\/oyae283"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.3390\/curroncol31110484","article-title":"Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting","volume":"31","author":"Manna","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.3390\/curroncol31110533","article-title":"Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer","volume":"31","author":"Cao","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early Breast Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the Diagnosis, Staging and Treatment of Patients with Metastatic Breast Cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2017.75.2311","article-title":"Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline","volume":"35","author":"Gilligan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline Testing in Patients with Breast Cancer: ASCO\u2013Society of Surgical Oncology Guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Iskander, R., Moyer, H., Vigneault, K., Mahmud, S.M., and Kimmelman, J. (2024). Survival Benefit Associated with Participation in Clinical Trials of Anticancer Drugs: A Systematic Review and Meta-Analysis. JAMA, 331.","DOI":"10.1001\/jama.2024.6281"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO-24-02263","article-title":"Endocrine Therapy Omission in Estrogen Receptor\u2013Low (1%\u201310%) Early-Stage Breast Cancer","volume":"43","author":"Choong","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Acs, B., Hartman, J., S\u00f6nmez, D., Lindman, H., Johansson, A.L.V., and Fredriksson, I. (2024). Real-World Overall Survival and Characteristics of Patients with ER-Zero and ER-Low HER2-Negative Breast Cancer Treated as Triple-Negative Breast Cancer: A Swedish Population-Based Cohort Study. Lancet Reg. Health-Eur., 40.","DOI":"10.1016\/j.lanepe.2024.100886"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10549-025-07628-3","article-title":"Pathologic Complete Response Rates of Patients with ER-Low\/HER2-Negative Breast Cancer Treated with Neoadjuvant Pembrolizumab plus Chemotherapy in the Neo-Real Study","volume":"211","author":"Bonadio","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and Chemotherapy in High-Risk, Early-Stage, ER+\/HER2\u2212 Breast Cancer: A Randomized Phase 3 Trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6475","DOI":"10.1245\/s10434-023-13846-0","article-title":"Clinical Behavior, Management, and Treatment Response of Estrogen Receptor Low (1\u201310%) Breast Cancer","volume":"30","author":"Moldoveanu","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clbc.2017.06.005","article-title":"Borderline ER-Positive Primary Breast Cancer Gains No Significant Survival Benefit From Endocrine Therapy: A Systematic Review and Meta-Analysis","volume":"18","author":"Chen","year":"2018","journal-title":"Clin. Breast Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.breast.2022.09.008","article-title":"Adjuvant Endocrine Therapy in Patients with Estrogen Receptor-Low Positive Breast Cancer: A Prospective Cohort Study","volume":"66","author":"Xie","year":"2022","journal-title":"Breast"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Jernstr\u00f6m, H., and Ryd\u00e9n, L. (2024). Into the Twilight Zone\u2014Should ER-Low Breast Cancer Be Treated as Triple Negative Breast Cancer?. Lancet Reg. Health-Eur., 40.","DOI":"10.1016\/j.lanepe.2024.100896"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rajagopal, P.S., Reid, S., Fan, R., Venton, L., Weidner, A., Roberson, M.L., Vadaparampil, S., Wang, X., Yoder, S., and Rosa, M. (2025). Population-Specific Patterns in Assessing Molecular Subtypes of Young Black Females with Triple-Negative Breast Cancer. npj Breast Cancer, 11.","DOI":"10.1038\/s41523-025-00731-0"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A Phase III Trial of Adjuvant Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Patients with HR-Positive\/HER2-Negative Early Breast Cancer: Final Invasive Disease-Free Survival Results from the NATALEE Trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","article-title":"Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor\u2013Positive, Human Epidermal Growth Factor Receptor 2\u2013Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes","volume":"42","author":"Rastogi","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","article-title":"American Society of Clinical Oncology\/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer","volume":"28","author":"Hammond","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10549-014-2980-0","article-title":"Germline BRCA Mutation Evaluation in a Prospective Triple-Negative Breast Cancer Registry: Implications for Hereditary Breast and\/or Ovarian Cancer Syndrome Testing","volume":"145","author":"Sharma","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa2005936","article-title":"A Population-Based Study of Genes Previously Implicated in Breast Cancer","volume":"384","author":"Hu","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","article-title":"Risk Reduction and Screening of Cancer in Hereditary Breast-Ovarian Cancer Syndromes: ESMO Clinical Practice Guideline","volume":"34","author":"Sessa","year":"2023","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_27","unstructured":"(2025, August 30). NICE Recommendations|Familial Breast Cancer: Classification, Care and Managing Breast Cancer and Related Risks in People with a Family History of Breast Cancer|Guidance|NICE. Available online: https:\/\/www.nice.org.uk\/guidance\/cg164\/chapter\/Recommendations#care-of-people-in-secondary-care-and-specialist-genetic-clinics."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41431-023-01507-5","article-title":"EMQN Best Practice Guidelines for Genetic Testing in Hereditary Breast and Ovarian Cancer","volume":"32","author":"McDevitt","year":"2024","journal-title":"Eur. J. Hum. Genet. EJHG"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","article-title":"Clinical Practice Guidelines for BRCA1 and BRCA2 Genetic Testing","volume":"146","author":"Pujol","year":"2021","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Weber, E., Carmona-Gonzalez, C.A., Boucher, M., Eisen, A., Laing, K., Melvin, J., Schrader, K.A., Sehdev, S., Wong, S.M., and Gelmon, K.A. (2025). Canadian Recommendations for Germline Genetic Testing of Patients with Breast Cancer: A Call to Action. Curr. Oncol., 32.","DOI":"10.20944\/preprints202503.2053.v1"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamaoncol.2015.4508","article-title":"Time to Surgery and Breast Cancer Survival in the United States","volume":"2","author":"Bleicher","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s11357-025-01719-1","article-title":"Quantifying the Impact of Treatment Delays on Breast Cancer Survival Outcomes: A Comprehensive Meta-Analysis","volume":"48","author":"Ungvari","year":"2026","journal-title":"GeroScience"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1245\/s10434-019-08050-y","article-title":"Time to Surgery and the Impact of Delay in the Non-Neoadjuvant Setting on Triple-Negative Breast Cancers and Other Phenotypes","volume":"27","author":"Mateo","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ijc.31411","article-title":"Time from Breast Cancer Diagnosis to Therapeutic Surgery and Breast Cancer Prognosis: A Population-based Cohort Study","volume":"143","author":"Eriksson","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s10549-019-05404-8","article-title":"Time-to-Surgery and Overall Survival after Breast Cancer Diagnosis in a Universal Health System","volume":"178","author":"Eaglehouse","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"11941","DOI":"10.1007\/s00432-023-05060-y","article-title":"Does Timing of Neoadjuvant Chemotherapy Influence the Prognosis in Patients with Early Triple Negative Breast Cancer?","volume":"149","author":"Hatzipanagiotou","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"De Azambuja, E., Trapani, D., Loibl, S., Delaloge, S., Senkus, E., Criscitiello, C., Poortmans, P., Gnant, M., Di Cosimo, S., and Cortes, J. (2020). ESMO Management and Treatment Adapted Recommendations in the COVID-19 Era: Breast Cancer. ESMO Open, 5.","DOI":"10.1136\/esmoopen-2020-000793"},{"key":"ref_38","unstructured":"(2025, December 02). Operational Approach Based on 3 Pillars. Available online: https:\/\/www.who.int\/initiatives\/global-breast-cancer-initiative\/operational-approach-based-on-3-pillars."},{"key":"ref_39","unstructured":"(2026, January 20). Measuring Cancer Surgery Wait Times in Ontario\u2014Health Quality Ontario. Available online: https:\/\/www.hqontario.ca\/System-Performance\/Measuring-System-Performance\/Measuring-Wait-Times-for-Cancer-Surgeries."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_41","unstructured":"(2025, December 18). Choosing Wisely\u2014ASCO. Available online: https:\/\/www.asco.org\/news-initiatives\/current-initiatives\/cancer-care-initiatives\/value-cancer-care\/choosing-wisely."},{"key":"ref_42","first-page":"43","article-title":"American Cancer Society\/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline","volume":"66","author":"Runowicz","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7026","DOI":"10.1245\/s10434-023-13977-4","article-title":"Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node Negative T1 Triple Negative Breast Cancer","volume":"30","author":"Huang","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Han, H.S., Vikas, P., Costa, R.L.B., Jahan, N., Taye, A., and Stringer-Reasor, E.M. (2023). Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between. Am. Soc. Clin. Oncol. Educ. Book, 43.","DOI":"10.1200\/EDBK_390464"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2020.04.033","article-title":"Adjuvant Chemotherapy in Small Node-Negative Triple-Negative Breast Cancer","volume":"135","author":"Steenbruggen","year":"2020","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.clbc.2025.05.022","article-title":"Adjuvant Chemotherapy in Early Triple-Negative Breast Cancer (T1a-c N0M0): A Systematic Review and Meta-Analysis","volume":"25","author":"Moraes","year":"2025","journal-title":"Clin. Breast Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000546080","article-title":"St. Gallen\/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference","volume":"20","author":"Ditsch","year":"2025","journal-title":"Breast Care"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/cncr.32878","article-title":"Adjuvant Chemotherapy for Small, Lymph Node\u2013Negative, Triple-negative Breast Cancer: A Single-center Study and a Meta-analysis of the Published Literature","volume":"126","author":"An","year":"2020","journal-title":"Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-021-06481-4","article-title":"Benefit of Adjuvant Chemotherapy in Node-Negative T1a versus T1b and T1c Triple-Negative Breast Cancer","volume":"192","author":"Fasano","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clbc.2023.08.002","article-title":"Assessment of Use and Impact of Chemotherapy in Lymph Node-Negative, T1a Triple-Negative Breast Cancer","volume":"23","author":"Zhang","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10549-023-07132-6","article-title":"Benefit of Adjuvant Chemotherapy in Lymph Node-Negative, T1b and T1c Triple-Negative Breast Cancer","volume":"203","author":"Bernal","year":"2024","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2012). Comparisons between Different Polychemotherapy Regimens for Early Breast Cancer: Meta-Analyses of Long-Term Outcome among 100 000 Women in 123 Randomised Trials. Lancet, 379, 432\u2013444.","DOI":"10.1016\/S0140-6736(11)61625-5"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1200\/JCO.2008.18.4028","article-title":"Docetaxel with Cyclophosphamide Is Associated with an Overall Survival Benefit Compared with Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735","volume":"27","author":"Jones","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.2016.71.4147","article-title":"Anthracyclines in Early Breast Cancer: The ABC Trials\u2014USOR 06-090, NSABP B-46-I\/USOR 07132, and NSABP B-49 (NRG Oncology)","volume":"35","author":"Blum","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1200\/JCO.23.01428","article-title":"Long-Term Follow-Up of the Anthracyclines in Early Breast Cancer Trials (USOR 06-090, NSABP B-46-I\/USOR 07132, and NSABP B-49 [NRG Oncology])","volume":"42","author":"Geyer","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","article-title":"Carboplatin in BRCA1\/2-Mutated and Triple-Negative Breast Cancer BRCAness Subgroups: The TNT Trial","volume":"24","author":"Tutt","year":"2018","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.31144","article-title":"Acute Myeloid Leukemia and Myelodysplastic Syndrome after Adjuvant Chemotherapy: A Population-based Study among Older Breast Cancer Patients","volume":"124","author":"Rosenstock","year":"2018","journal-title":"Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10549-025-07778-4","article-title":"Omission of Anthracyclines from Neoadjuvant Chemotherapy for Breast Cancer: A Population-Based Analysis","volume":"213","author":"Mata","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_60","unstructured":"Tolaney, S. (2025, December 12). ASCO Guideline Addresses Controversial Areas in Adjuvant Therapy for Breast Cancer. Available online: https:\/\/ascopost.com\/issues\/august-25-2016\/asco-guideline-addresses-controversial-areas-in-adjuvant-therapy-for-breast-cancer\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3747\/co.27.6147","article-title":"Baseline Staging Imaging for Distant Metastasis in Women with Stages I, II, and III Breast Cancer","volume":"27","author":"Arnaout","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"426","DOI":"10.6004\/jnccn.2025.0053","article-title":"NCCN Guidelines\u00ae Insights: Breast Cancer, Version 5.2025: Featured Updates to the NCCN Guidelines","volume":"23","author":"Gradishar","year":"2025","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<500::AID-CNCR11>3.0.CO;2-7","article-title":"Pelvic Computed Tomography of Breast Carcinoma Patients: Should It Routinely Be Added to Abdominal Computed Tomography?","volume":"79","author":"Meyer","year":"1997","journal-title":"Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2214\/ajr.176.6.1761433","article-title":"Breast Cancer: Assessing the Use of Routine Pelvic CT in Patient Evaluation","volume":"176","author":"Drotman","year":"2001","journal-title":"Am. J. Roentgenol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO-24-01875","article-title":"Adjuvant Dose-Dense Chemotherapy in Hormone Receptor\u2013Positive Breast Cancer","volume":"43","author":"Ballman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2015.60.9271","article-title":"Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer","volume":"33","author":"Sparano","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-Term Efficacy and Safety of Addition of Carboplatin with or without Veliparib to Standard Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: 4-Year Follow-up Data from BrighTNess, a Randomized Phase III Trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the Addition of Carboplatin and\/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)","volume":"33","author":"Sikov","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant Carboplatin in Patients with Triple-Negative and HER2-Positive Early Breast Cancer (GeparSixto; GBG 66): A Randomised Phase 2 Trial","volume":"15","author":"Schneeweiss","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","article-title":"Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Mason, S.R., Willson, M.L., Egger, S.J., Beith, J., Dear, R.F., and Goodwin, A. (2024). Platinum Chemotherapy for Early Triple-Negative Breast Cancer. Breast, 75.","DOI":"10.1016\/j.breast.2024.103712"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Sharma, P., Stecklein, S.R., Yoder, R., Staley, J.M., Schwensen, K., O\u2019Dea, A., Nye, L., Satelli, D., Crane, G., and Madan, R. (2024). Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol., 10.","DOI":"10.1001\/jamaoncol.2023.5033"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1200\/JCO.23.01935","article-title":"Optimizing Postneoadjuvant Treatment in Patients with Early Breast Cancer Achieving Pathologic Complete Response","volume":"42","author":"Valenza","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Stecklein, S.R., Kimler, B.F., Yoder, R., Schwensen, K., Staley, J.M., Khan, Q.J., O\u2019Dea, A.P., Nye, L.E., Elia, M., and Heldstab, J. (2023). ctDNA and Residual Cancer Burden Are Prognostic in Triple-Negative Breast Cancer Patients with Residual Disease. npj Breast Cancer, 9.","DOI":"10.1038\/s41523-023-00512-7"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-Free Survival by Residual Cancer Burden with Pembrolizumab in Early-Stage TNBC: Exploratory Analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa1111065","article-title":"Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer","volume":"366","author":"Eidtmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall Survival in the OlympiA Phase III Trial of Adjuvant Olaparib in Patients with Germline Pathogenic Variants in BRCA1\/2 and High-Risk, Early Breast Cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Garber, J., Cameron, D., Campbell, C., Yothers, G., Taboada, M., El-Abed, S., Rastogi, P., Paterson, V., Kang, J., and Zafonte, S. (2025). Abstract GS1-09: OlympiA: A Phase 3, Multicenter, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib after (Neo)Adjuvant Chemotherapy in Patients w\/Germline BRCA1 & BRCA2 Pathogenic Variants & Highrisk HER2-Negative Primary Breast Cancer. Clin. Cancer Res., 31.","DOI":"10.1158\/1557-3265.SABCS24-GS1-09"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ejca.2022.02.003","article-title":"Effects of Capecitabine as Part of Neo-\/Adjuvant Chemotherapy\u2014A Meta-Analysis of Individual Breast Cancer Patient Data from 13 Randomised Trials Including 15,993 Patients","volume":"166","author":"Seither","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Di Lisa, F.S., Krasniqi, E., Pizzuti, L., Barba, M., Cannita, K., De Giorgi, U., Borella, F., Foglietta, J., Cariello, A., and Ferro, A. (2023). Adjuvant Capecitabine in Triple Negative Breast Cancer Patients with Residual Disease after Neoadjuvant Treatment: Real-World Evidence from CaRe, a Multicentric, Observational Study. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1152123"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Lee, S., Hyung, J., Jeong, H., Ahn, J.-H., Jung, K.H., Kim, S.-B., Lee, H.J., Gong, G., Kim, H.J., and Lee, J.W. (2024). 265P Association of Clinical Benefit of Adjuvant Capecitabine and RCB Class in Triple Negative Breast Cancer (TNBC) Patients with Residual Disease Following Neoadjuvant Chemotherapy. Ann. Oncol., 35.","DOI":"10.1016\/j.annonc.2024.08.208"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ma, Y., Zhu, M., Zhang, J., Jiao, D., Hou, Y., Chen, X., and Liu, Z. (2025). Efficacy of Adjuvant Capecitabine in Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Therapy: A Real-World Study. Breast, 81.","DOI":"10.1016\/j.breast.2025.104477"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Zujewski, J.A., and Rubinstein, L. (2017). CREATE-X a Role for Capecitabine in Early-Stage Breast Cancer: An Analysis of Available Data. npj Breast Cancer, 3.","DOI":"10.1038\/s41523-017-0029-3"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Page, D., Pucilowska, J., Bennetts, L., Kim, I., Sanchez, K., Martel, M., Conlin, A., Moxon, N., Mellinger, S., and Acheson, A. (2019). Abstract P2-09-03: Updated Efficacy of First or Second-Line Pembrolizumab (Pembro) plus Capecitabine (Cape) in Metastatic Triple Negative Breast Cancer (mTNBC) and Correlations with Baseline Lymphocyte and Na\u00efve CD4+ T-Cell Count. Cancer Res., 79.","DOI":"10.1158\/1538-7445.SABCS18-P2-09-03"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Shah, A.N., Flaum, L., Helenowski, I., Santa-Maria, C.A., Jain, S., Rademaker, A., Nelson, V., Tsarwhas, D., Cristofanilli, M., and Gradishar, W. (2020). Phase II Study of Pembrolizumab and Capecitabine for Triple Negative and Hormone Receptor-Positive, HER2\u2212negative Endocrine-Refractory Metastatic Breast Cancer. J. Immunother. Cancer, 8.","DOI":"10.1136\/jitc-2019-000173"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and Durvalumab in Patients with Germline BRCA-Mutated Metastatic Breast Cancer (MEDIOLA): An Open-Label, Multicentre, Phase 1\/2, Basket Study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Vinayak, S., Tolaney, S.M., Schwartzberg, L., Mita, M., McCann, G., Tan, A.R., Wahner-Hendrickson, A.E., Forero, A., Anders, C., and Wulf, G.M. (2019). Open-Label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncol., 5.","DOI":"10.1001\/jamaoncol.2019.1029"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1158\/1078-0432.CCR-25-1818","article-title":"KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy","volume":"32","author":"Rugo","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.2014.57.2461","article-title":"Comparison of Breast Cancer Recurrence and Outcome Patterns Between Patients Treated From 1986 to 1992 and From 2004 to 2008","volume":"33","author":"Cossetti","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Durbin, S.M., Zubiri, L., Perlman, K., Wu, C.-Y., Lim, T., Grealish, K., Hathaway, N., LoPiccolo, J., Wang, M., and Falade, A. (2025). Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. JAMA Netw. Open, 8.","DOI":"10.1001\/jamanetworkopen.2025.2668"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1200\/JCO.2005.03.2235","article-title":"Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care","volume":"24","author":"Grunfeld","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Carvalho, F.M. (2025). Targeting Low-Risk Triple-Negative Breast Cancer: A Review on de-Escalation Strategies for a New Era. Transl. Breast Cancer Res., 6.","DOI":"10.21037\/tbcr-24-28"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Kesson, E.M., Allardice, G.M., George, W.D., Burns, H.J.G., and Morrison, D.S. (2012). Effects of Multidisciplinary Team Working on Breast Cancer Survival: Retrospective, Comparative, Interventional Cohort Study of 13 722 Women. BMJ, 344.","DOI":"10.1136\/bmj.e2718"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1097\/MS9.0000000000000914","article-title":"The Effect of Multidisciplinary Team on Survival Rates of Women with Breast Cancer: A Systematic Review and Meta-Analysis","volume":"85","author":"Pangarsa","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Punie, K., Kurian, A.W., Ntalla, I., Sjekloca, N., Estrin, A., Dabrowski, E.C., Lai, C., and Hurvitz, S. (2025). Unmet Need for Previously Untreated Metastatic Triple-Negative Breast Cancer: A Real-World Study of Patients Diagnosed from 2011 to 2022 in the United States. Oncologist, 30.","DOI":"10.1093\/oncolo\/oyaf034"},{"key":"ref_100","unstructured":"Gennari, A., Martins Branco, D., Trapani, D., Pentheroudakis, G., Curigliano, G., and Harbeck, N. (2025, December 12). ESMO Living Guideline: Metastatic Breast Cancer v1.2. Available online: https:\/\/www.esmo.org\/guidelines\/living-guidelines\/esmo-living-guideline-metastatic-breast-cancer."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2016.70.1474","article-title":"Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"35","author":"Ferrell","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1200\/JCO.22.00503","article-title":"Neoadjuvant Chemotherapy, Endocrine Therapy; Targeted Therapy for Breast Cancer Guideline Expert Panel. Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update","volume":"40","author":"Korde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1200\/JCO.21.01374","article-title":"Chemotherapy and Targeted Therapy for Patients with Human Epidermal Growth Factor Receptor 2\u2013Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor\u2013Negative: ASCO Guideline Update","volume":"39","author":"Moy","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/annonc\/mdp028","article-title":"Does Confirmatory Tumor Biopsy Alter the Management of Breast Cancer Patients with Distant Metastases?","volume":"20","author":"Simmons","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Boman, C., Zerdes, I., M\u00e5rtensson, K., Bergh, J., Foukakis, T., Valachis, A., and Matikas, A. (2021). Discordance of PD-L1 Status between Primary and Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. Cancer Treat. Rev., 99.","DOI":"10.1016\/j.ctrv.2021.102257"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus Chemotherapy versus Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000510812","article-title":"Understanding PD-L1 Testing in Breast Cancer: A Practical Approach","volume":"15","author":"Erber","year":"2020","journal-title":"Breast Care"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Jin, J., Gao, Y., Zhang, J., Wang, L., Wang, B., Cao, J., Shao, Z., and Wang, Z. (2018). Incidence, Pattern and Prognosis of Brain Metastases in Patients with Metastatic Triple Negative Breast Cancer. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4371-0"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The Incidence of Brain Metastases among Patients with Metastatic Breast Cancer: A Systematic Review and Meta-Analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro-Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Cardoso, F., Paluch-Shimon, S., Schumacher-Wulf, E., Matos, L., Gelmon, K., Aapro, M.S., Bajpai, J., Barrios, C.H., Bergh, J., and Bergsten-Nordstr\u00f6m, E. (2024). 6th and 7th International Consensus Guidelines for the Management of Advanced Breast Cancer (ABC Guidelines 6 and 7). Breast, 76.","DOI":"10.1016\/j.breast.2024.103756"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1200\/JCO-25-00356","article-title":"Brain Imaging Surveillance for Patients with Metastatic Breast Cancer: A Randomized Clinical Trial Is Required to Guide Practice","volume":"43","author":"Jerzak","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/noaf018","article-title":"Phase II Trial of Brain MRI Surveillance in Stage IV Breast Cancer","volume":"27","author":"Ahmed","year":"2025","journal-title":"Neuro-Oncology"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Kim, G.M., Sohn, J.H., Kim, M.H., Kim, S.-G., Park, H.S., Jang, J.H., Kim, Y.B., and Lee, S. (2024). Abstract PO2-27-09: Clinical Impact of Routine MRI Screening for Brain Metastases in Patients with HER2 Positive or Triple Negative Metastatic Breast Cancer. Cancer Res., 84.","DOI":"10.1158\/1538-7445.SABCS23-PO2-27-09"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.19.02767","article-title":"Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients with Brain Metastases: Phase III Trial NRG Oncology CC001","volume":"38","author":"Brown","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Lebow, E.S., Pike, L.R.G., Seidman, A.D., Moss, N., Beal, K., and Yu, Y. (2023). Symptomatic Necrosis with Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases. JAMA Oncol., 9.","DOI":"10.1001\/jamaoncol.2023.4492"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S3703","DOI":"10.1016\/S0167-8140(25)03395-X","article-title":"4468 Use of CBCT as a Quality Assurance Tool for Frame-Based SRS Treatments","volume":"206","author":"Rivera","year":"2025","journal-title":"Radiother. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijrobp.2023.07.015","article-title":"A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and International Stereotactic Radiosurgery Society Recommendations","volume":"118","author":"Vellayappan","year":"2024","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Jerzak, K.J., Shum, M., Pond, G., Freedman, O., Chandhoke, G., Conrad, T., Brastianos, P., Stanisz, G., Sahgal, A., and Warner, E. (2024). Abstract 4798: MRI Screening for Brain Metastases (BrM) versus SYMptom-Directed Brain Imaging for Patients with Triple Negative (TN) or HER2+ Metastatic Breast Cancer (MBC): An Ad-Hoc Interim Analysis of a Randomized Phase II Pilot Study. Cancer Res., 84.","DOI":"10.1158\/1538-7445.AM2024-4798"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early Palliative Care for Patients with Metastatic Non\u2013Small-Cell Lung Cancer","volume":"363","author":"Temel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Kang, E., Kang, J.H., Koh, S.-J., Kim, Y.J., Seo, S., Kim, J.H., Cheon, J., Kang, E.J., Song, E.-K., and Nam, E.M. (2024). Early Integrated Palliative Care in Patients with Advanced Cancer: A Randomized Clinical Trial. JAMA Netw. Open, 7.","DOI":"10.1001\/jamanetworkopen.2024.26304"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Adenis, A., Silva, A.D., Abdelghani, M.B., Bourgeois, V., Bogart, E., Turpin, A., Evin, A., Proux, A., Galais, M.-P., and Jaraudias, C. (2024). Early Palliative Care and Overall Survival in Patients with Metastatic Upper Gastrointestinal Cancers (EPIC): A Multicentre, Open-Label, Randomised Controlled Phase 3 Trial. eClinicalMedicine, 74.","DOI":"10.1016\/j.eclinm.2024.102470"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"136","DOI":"10.6004\/jnccn.2021.7040","article-title":"Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients with Metastatic Breast Cancer","volume":"20","author":"Greer","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.annonc.2024.04.001","article-title":"IMpassion132 Double-Blind Randomised Phase III Trial of Chemotherapy with or without Atezolizumab for Early Relapsing Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer","volume":"35","author":"Dent","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.annonc.2021.05.355","article-title":"First-Line Atezolizumab plus Nab-Paclitaxel for Unresectable, Locally Advanced, or Metastatic Triple-Negative Breast Cancer: IMpassion130 Final Overall Survival Analysis","volume":"32","author":"Emens","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_125","unstructured":"F. Hoffmann-La Roche Ltd (2025, December 12). Roche Provides Update on Tecentriq US Indication for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer. Available online: https:\/\/www.globenewswire.com\/news-release\/2021\/08\/27\/2287799\/0\/en\/Roche-provides-update-on-Tecentriq-US-indication-for-PD-L1-positive-metastatic-triple-negative-breast-cancer.html."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.annonc.2021.05.801","article-title":"Primary Results from IMpassion131, a Double-Blind, Placebo-Controlled, Randomised Phase III Trial of First-Line Paclitaxel with or without Atezolizumab for Unresectable Locally Advanced\/Metastatic Triple-Negative Breast Cancer","volume":"32","author":"Miles","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab Govitecan-Hziy in Refractory Metastatic Triple-Negative Breast Cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Carey, L.A., Loirat, D., Punie, K., Bardia, A., Di\u00e9ras, V., Dalenc, F., Diamond, J.R., Fontaine, C., Wang, G., and Rugo, H.S. (2022). Sacituzumab Govitecan as Second-Line Treatment for Metastatic Triple-Negative Breast Cancer\u2014Phase 3 ASCENT Study Subanalysis. npj Breast Cancer, 8.","DOI":"10.1038\/s41523-022-00439-5"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/onc.2012.151","article-title":"The Trop-2 Signalling Network in Cancer Growth","volume":"32","author":"Guerra","year":"2013","journal-title":"Oncogene"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/onc.2012.36","article-title":"Upregulation of Trop-2 Quantitatively Stimulates Human Cancer Growth","volume":"32","author":"Trerotola","year":"2013","journal-title":"Oncogene"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Tolaney, S.M., De Azambuja, E., Kalinsky, K., Loi, S., Kim, S.-B., Yam, C., Rapoport, B.L., Im, S.-A., Pistilli, B., and McHayleh, W. (2025). Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1\u2013Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results from the Randomized Phase 3 ASCENT-04\/KEYNOTE-D19 Study. J. Clin. Oncol., 43.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14712598.2021.1936494","article-title":"Antibody-Drug Conjugates, Immune-Checkpoint Inhibitors, and Their Combination in Breast Cancer Therapeutics","volume":"21","author":"Saini","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_134","first-page":"S1682","article-title":"LBA22 Patient-Reported Outcomes (PROs) with Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) vs Chemotherapy (Chemo) + Pembro in Patients (Pts) with Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer (mTNBC) in the Phase III ASCENT-04\/KEYNOTE-D19 Study","volume":"36","author":"Schmid","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer","volume":"393","author":"Punie","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_137","first-page":"S1","article-title":"First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Patients with Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mTNBC) for Whom Immunotherapy Was Not an Option: Primary Results from the Randomised, Phase III TROPION-Breast02 Trial","volume":"2025","author":"Dent","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus Chemotherapy in Patients with Germline BRCA1\/2-Mutated HER2-Negative Advanced Breast Cancer: Final Overall Survival Results from the EMBRACA Trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1200\/JCO.20.00299","article-title":"Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline","volume":"38","author":"Tung","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Egger, S.J., Chan, M.M.K., Luo, Q., and Wilcken, N. (2020). Platinum-Containing Regimens for Triple-Negative Metastatic Breast Cancer. Cochrane Database Syst. Rev., 2020.","DOI":"10.1002\/14651858.CD013750"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1038\/s41416-022-02003-1","article-title":"Outcomes of Patients with HER2-Negative Metastatic Breast Cancer after Platinum- and Non-Platinum-Based First-Line Chemotherapy among Patients with and without Pathogenic Germline BRCA1\/2 Mutations","volume":"127","author":"Jacot","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Pacholczak-Madej, R., Meluch, M., and P\u00fcsk\u00fcll\u00fco\u011flu, M. (2025). Sequencing of Antibody Drug Conjugates in Breast Cancer: Evidence Gap and Future Directions. Biochim. Biophys. Acta BBA-Rev. Cancer, 1880.","DOI":"10.1016\/j.bbcan.2025.189369"},{"key":"ref_146","unstructured":"Poumeaud, F. (2025, January 12). ePoster 1052: Evidence Accumulates Against Sequencing Topo1-ADCs in HER2-Low Metastatic Breast Cancers: Results from International, Retrospective, Real-World ADC-Low-Europe Cohort. Proceedings of the SABCS 2025, San Antonio, TX, USA."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T11:21:45Z","timestamp":1778844105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/5\/243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":146,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["curroncol33050243"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33050243","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}